Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

Summary

TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in patients with COVID-19 infection. These results will lead to and inform a Phase III randomized placebo-controlled trial.

Timeline

Start

2020-04-24

Primary completion

2021-02-02

Completion

2021-04-01

Drugs

Indications